mexican patients
Recently Published Documents


TOTAL DOCUMENTS

660
(FIVE YEARS 172)

H-INDEX

29
(FIVE YEARS 4)

Author(s):  
Elisa Bribiesca-Contreras ◽  
Christian García-Estrada ◽  
Enrique Gómez-Figueroa ◽  
Lizeth Zertuche-Ortuño ◽  
Roberto Rodríguez-Rivas ◽  
...  

Pathogens ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 14
Author(s):  
Adrian Canizalez-Roman ◽  
Juan E. Reina-Reyes ◽  
Uriel A. Angulo-Zamudio ◽  
Eloy E. Geminiano-Martínez ◽  
Antonio F. Flores-Carrillo ◽  
...  

Colon diseases, such as colorectal cancer (CRC), are multifactor diseases that affect more than one million people per year; recently, the microbiota has been associated with an etiologic factor, specifically bacterial cyclomodulin positivity (CM+). Unfortunately, there are no studies from Mexico that detail the presence of bacterial CM+ in patients with colon diseases. We therefore performed a comprehensive study to investigate the associations and prevalence of cyclomodulin-positive Diarrheagenic E. coli (DEC), non-DEC, and Klebsiella spp. strains isolated from Mexican subjects with colon diseases. In this work, we analyzed 43 biopsies, 87 different bacteria were isolated, and E. coli was the most frequently noted, followed by Klebsiella spp., and Enterococcus spp. E. coli, non-DEC, and EPEC belonging to phylogroup B2 were the most prevalent. More than 80% of E. coli and Klebsiella were CM+. pks, cdt, cnf, and cif were identified. cdt was associated with non-DEC, cif and its combinations with EPEC, as well as cdt and psk with Klebsiella. Lastly, all the CM+ bacteria were resistant to at least one antibiotic (34% were MDR, and 48% XDR). In conclusion, the high prevalence of bacterial CM+ in colon disease patients suggests that these bacteria play an important role in the genesis of these diseases.


2021 ◽  
pp. 1-13
Author(s):  
Rosario Lissiet Romero Coripuna ◽  
Delia Irazú Hernández Farías ◽  
Blanca Olivia Murillo Ortiz ◽  
Teodoro Córdova Fraga

Breast cancer is a very important health concern around the world. Early detection of such a disease increases the chances of survival. Among the available screening tools, there is the Electro-Impedance Mammography (EIM), which is a novel and less invasive method that captures the potential difference stored in breast tissues under the assumption that electrical properties among normal and pathologically altered tissues are different. In this paper, we address breast cancer detection as a multi-class problem aiming to determine the corresponding label in terms of the Breast Imaging Electrical Impedance classification system, the standard used by physicians for interpreting an EIM mammogram. For experimental purposes, for the first time in the literature, we took advantage of a dataset comprising EIM of Mexican patients. Aiming to establish a baseline for this task, traditional supervised learning methods were used together with two different feature extraction techniques: raw pixel data and transfer learning. Besides, data augmentation was exploited for compensating data imbalance. Different experimental settings were evaluated reaching classification rates over 0.85 in F-score. KNN emerges as a very promising classifier for addressing this task. The obtained results allow us to validate the usefulness of traditional methods for classifying electro-impedance mammograms.


2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Blanca E. Ríos-González ◽  
Jessica F. Rodríguez-Ortiz ◽  
Anna G. Castro-Martínez ◽  
María T. Magaña-Torres ◽  
Patricio Barros-Núñez

Amino Acids ◽  
2021 ◽  
Author(s):  
Mayra Paloma Macías-Acosta ◽  
Lorena Valerdi-Contreras ◽  
Ericka Denise Bustos-Angel ◽  
Rudy Antonio García-Reyes ◽  
Monserrat Alvarez-Zavala ◽  
...  

2021 ◽  
Author(s):  
Violeta Larios-Serrato ◽  
José Darío Martínez-Ezquerro ◽  
Hilda-Alicia Valdez-Salazar ◽  
Javier Torres ◽  
Margarita Camorlinga-Ponce ◽  
...  

Gastric cancer (GC) is a malignancy with the highest mortality among diseases of the digestive system worldwide. The study of GC-alterations is crucial to understand tumor biology, to establish important aspects of cancer prognosis and treatment response. Here, we purified DNA and performed whole-genome analysis with high-density arrays in samples from Mexican patients diagnosed with GC: diffuse (DGC) or intestinal (IGC), or non-atrophic gastritis (NAG) samples that served as controls. We identified shared and unique copy number alterations (CNA) between these altered tissues involving key genes and signaling pathways associated with cancer, allowing their molecular distinction and identification of the most relevant molecular functions impacted. When focused on epithelial-mesenchymal transition (EMT) genes, our bioinformatic analysis revealed that the altered network associated with chromosomal alterations included 11 genes shared between DGC, IGC, and NAG, as well as 19 DGC- and 7 IGC-exclusive genes, whose main molecular functions included adhesion, angiogenesis, migration, metastasis, morphogenesis, proliferation, and survival. This study presents the first whole-genome high-density array study in GC from Mexican patients and reveals shared and exclusive CNA-genes in DGC and IGC. In addition, we provide a bioinformatically predicted network focused on CNA-altered genes involved in the EMT, associated with the hallmarks of cancer, as well as precancerous alterations that could lead to gastric cancer. Implications: Molecular signatures of diffuse and intestinal GC, predicted bioinformatically, involve common and distinct CNA-EMT genes related to the hallmarks of cancer that are potential candidates for screening GC biomarkers, including early stages.


Cancers ◽  
2021 ◽  
Vol 13 (22) ◽  
pp. 5602
Author(s):  
Galo Méndez-Matías ◽  
Cindy Velázquez-Velázquez ◽  
Rosario Castro-Oropeza ◽  
Alejandra Mantilla-Morales ◽  
Diana Ocampo-Sandoval ◽  
...  

Head and neck squamous cell carcinomas (HNSCC) show a variety of biological and clinical characteristics that could depend on the association with the human papillomavirus (HPV). Biological and clinical characterization is essential to stratify patients based on prognostic and predictive factors. Reports on HNSCC are scarce in Mexico. Herein, we analyzed 414 Mexican patients with HNSCC, including oropharynx (OPSCC), larynx (LASCC), and oral cavity (OCSCC), and identified HPV DNA and p16 expression. Global gene expression profiles were analyzed in 25 HPV+/p16+ vs. HPV−/p16− cases. We found 32.3% p16+ and 22.3% HPV+ samples, HPV 16, 18, 39, 52, and 31 being the most frequent genotypes. For OPSCC, LASCC and OCSCC, 39.2, 14.7, and 9.6% were HPV+/p16+, respectively. High expression of SLIRP, KLF10, AREG, and LIMA was associated with poor survival; in contrast, high expression of MYB and SYCP2 correlated with better survival. In HPV+ cases, high expression of SLC25A39 and GJB2 was associated with poor survival. Likewise, EGFR, IL-1, IL-6, JAK-STAT, WNT, NOTCH, and ESR1 signaling pathways were downregulated in HPV+ cases. CSF1R, MYC, and SRC genes were identified as key hubs and therapeutic targets. Our study offers information regarding the molecular and clinical characteristics of HNSCC in Mexican patients.


Author(s):  
Maximiliano Barrera-Sanchez ◽  
Julio C. Hernandez-Camarena ◽  
Raul E. Ruiz-Lozano ◽  
Jorge E. Valdez-Garcia ◽  
Alejandro Rodriguez-Garcia

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 3367-3367
Author(s):  
Emmanuel Almanza Huante ◽  
Juan Rangel-Patiño ◽  
Rosana Daniela Córdova-Serrano ◽  
Karla Adriana Espinosa ◽  
Roberta Demichelis

Abstract Introduction: "Philadelphia like" ALL has been related to poor prognosis. CRLF2 over-expression (cytokine receptor like factor-2) has been found in up to 50% of patients with Philadelphia-like ALL and its expression can be measured by Flow Cytometry (FC). CRLF2 over-expression is more common in Hispanic population (45-68%) however, there is no current recommendation in using it as a prognostic marker. Objectives: Find the prevalence of CRLF2 overexpression measured by FC, in adult Mexican patients with treatment-naïve ALL Describe the outcomes of the patients who over-expressed CRLF2 by Complete Response (CR), Minimal Residual Disease (MRD), Leukemia-Free Survivale (LFS) and Overall Survival (OS). Methodology: This is a retrospective cohort study in adults with newly diagnosed ALL from two reference centers in Mexico City. We measured CRLF2 expression by FC in fresh bone marrow samples from treatment-naïve patients at one location; to define over-expression, samples were first analyzed by two different experts who grouped the cases in over-expression or no overexpression using Mean Fluorescence Intensity (MFI) between two populations, blasts and controls (normal B cells). Outcomes were compared using chi-square test for binary variables and log-rank test for time-to-event variables with a p value <0.05 as significant. Results: From April 2018 to January 2020 46 patients with treatment-naïve B-cell ALL were evaluable; the median age was 29.5 years, 38 (82.6%) were Adolescents and Young Adults (AYA), 22 (47.8%) had leukocytosis, 15 (53.5%) of the evaluable karyotypes, were assigned to high-risk group. The median time of follow-up was 24.5 months and 19 (41.3%) patients were positive for CRLF2-overexpression. For the follow-up cohort all of the patients were evaluable for outcomes. CNS disease was detectable in 11(24.5%) patients which was higher in CRLF2-overexpresed patients (15.5% vs 8.9%, p=0.015). We found no difference in Complete Remission (CR) in CRLF2 status but a high tendency for R/R (Relapse/Refractory) disease (83.3% in CRLF2-overexpression vs 60% in CRLF2 negative group; p=0.09) and dead (63.2% in CRLF2-overexpression vs 37% in CRLF2 negative group; p=0.07). MRD1, 2 and 3 (1=after induction, 2= week 16 and 3= before maintenance) was significantly worse in patients with CRLF2 overexpression (1=15.8% vs 58.3%, p<0.01; 2=7.1% vs 52.6%, p<0.01; 3=0% vs 55.6%, p<0.05). Overall Survival was significantly worse in patients with CRLF2 overexpression (Median Not Reached vs 11.05 months; p=0.04) (Figure 1); Disease-Free Survival (DFS) had a tendency towards worse outcome in patients with CRLF2 overexpression (18.48 vs 5.82 months, p=0.07) (Figure 2). Conclusion: Survival in patients who have CRLF2 overexpression is significantly worse when measured by FC, this might be related to early high-risk markers as MRD. CRLF2 overexpression in this hispanic sample was higher (41%) than other reports. CRLF2 measured as a prognostic factor by FC needs to be further considered due to the high availability of this technique across Latin-America. Figure 1 Figure 1. Disclosures Rangel-Patiño: Abbvie: Speakers Bureau; Bristol: Consultancy. Espinosa: Pfizer: Consultancy; Amgen: Speakers Bureau; Janssen: Consultancy. Demichelis: Novartis: Consultancy, Research Funding, Speakers Bureau; Gilead: Consultancy; Bristol/Celgene: Consultancy, Speakers Bureau; Jazz: Consultancy; ASH: Research Funding; Astellas: Consultancy; AMGEN: Consultancy, Speakers Bureau; Abbvie: Consultancy, Speakers Bureau.


Sign in / Sign up

Export Citation Format

Share Document